A mixed picture of future growth and near term margin pressure; Hold Revitalizing in 2H 2017 1H 2017 Results remains solid. Maintain BUY In-line 1H 2017 Results. Tissue paper remains a growth driver Insulin slowed down, 6-APA positives reflected. Maintain HOLD. Virscend Education Interim Results Concerns about Q2 results put to rest. Optics business development will trigger a further re-rating. NEED MORE CONCRETE ACTION TO UNLOCK VALUE 1H 2017 Results In Line With Expectations. Maintain BUY. Lipusu looking gloomy. Execution in doubt. Downgrade to SELL.